| Cardiovascular Risk Management |
1 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.9 |
| Primary Care |
0 |
0.99 |
| Heart Failure (HF) |
0 |
0.54 |
| Hypertension |
0 |
0.52 |
| Chronic Kidney Disease |
0 |
0.43 |
| Renal Failure |
0 |
0.43 |
| Renal Disease |
0 |
0.41 |
| Kidney |
0 |
0.97 |
| Metabolism |
0 |
0.39 |
| Metabolic Syndrome |
0 |
0.32 |
| Cardiovascular disease |
0 |
0.98 |
| Cardiovascular Imaging |
0 |
0.27 |
| CT Scan |
0 |
0.22 |
| Clinical Guidelines |
0 |
0.19 |
| Endocrinology |
0 |
0.19 |
| Heart |
0 |
0.19 |
| Lipids Management |
0 |
0.19 |
| Michigan |
0 |
0.19 |
| Obesity |
0 |
0.19 |
| GLP-1 Receptor Agonist |
0 |
0.17 |
| Hepatic Fibrosis |
0 |
0.14 |
| A-Scan Biometry |
0 |
0.1 |
| ACE Inhibitor |
0 |
0.1 |
| Cardiovascular Stress Testing |
0 |
0.1 |
| Echocardiography |
0 |
0.1 |
| Hypertriglyceridemia |
0 |
0.1 |
| Liver |
0 |
0.1 |
| North Carolina |
0 |
0.1 |
| Ohio |
0 |
0.1 |
| Preventive Screening |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| Scan |
0 |
0.1 |
| SGLT2 Inhibitor |
0 |
0.1 |
| Care and Maintenance of Vision |
0 |
0.09 |
| Cataract |
0 |
0.09 |